Adagene Inc. (ADAG): Operating Income
-$21.44M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$21.44M | n/m | 2026-04-01, From 2025-01-01 |
| 2024-12-31 | -$35.95M | n/m | 2026-04-01, From 2024-01-01 |
| 2023-12-31 | -$23.72M | n/m | 2026-04-01, From 2023-01-01 |
| 2022-12-31 | -$83.92M | n/m | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | -$72.36M | n/m | 2024-03-29, From 2021-01-01 |
| 2020-12-31 | -$43.15M | n/m | 2023-04-28, From 2020-01-01 |
| 2019-12-31 | -$19.17M | n/m | 2022-04-26, From 2019-01-01 |
| 2018-12-31 | -$17.33M | n/a | 2021-04-28, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Adagene Inc. (ADAG) | 2025-12-31 | -$21.44M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$36.11M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$76.38M | n/m |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$373.07M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$22.56M | n/m |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$42.44M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$114.40M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$515.07M | n/m |
| Immunome Inc. (IMNM) | 2025-12-31 | -$224.11M | n/m |
Compare ADAG, BOLT, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗